Purpose: The ENCePP Code of Conduct provides a framework for scientifically independent and transparent pharmacoepidemiological research. Despite becoming a landmark reference, practical implementation of key provisions was still limited. The fourth revision defines scientific independence and clarifies uncertainties on the applicability to postauthorisation safety studies requested by regulators. To separate the influence of the funder from the investigator's scientific responsibility, the Code now requires that the lead investigator is not employed by the funding institution.
The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) was set up in 2008 to strengthen methodological standards, transparency, and scientific independence that supports the evaluation of medicines in Europe. 1 The ENCePP Code of Conduct, referred to hereafter as the Code, was first released in 2010 to set out a framework for good practise in the relationship between investigators and study funders, irrespective of whether the study funder was a public body, industry, or a regulatory authority. 2 The purpose was ultimately to improve the integrity of pharmacoepidemiological research, for the benefit of public health.
The ENCePP Code of Conduct is a tool supporting the dialogue between stakeholders in pharmacoepidemiological studies. The objective of this paper is to present the main provisions of the Code, focussing on the most recent revision, and to discuss the perspectives of the relevant stakeholders on its value and applicability.
2 | THE ENCEPP CODE OF CONDUCT
| The initial concept
The initial concept for the Code was a contractual framework between the study funder and the primary lead investigator that would seek to guarantee transparency and scientific independence. However, because of the different languages and legal systems existing across Europe, a standard template for the research contract between a research institution and a study funder was not deemed feasible, and the Code was launched as a set of principles and provisions to be integrated in each study contract. The contract was to be signed before the development of the study protocol.
A key requirement was the publication of study results, whether negative or positive, under the responsibility of the primary lead investigator. Transparency was granted by the creation of a publicly accessible electronic register, which later became the European Union (EU) Post-Authorisation Studies (PAS) Register (EU PAS Register), in which the study protocol was to be uploaded before data collection and in which the study report was to be uploaded when the study is finalised.
Since 2010, several revisions of the Code were published in light of experience with its uptake by stakeholders and in efforts to facilitate the implementation of its requirements on access to study data, declaration of interests, and funding sources; to improve its readability; and to provide clarifications.
Despite these revisions and whilst becoming a key reference for the conduct of pharmacoepidemiological studies over the years, the Code continued to experience limitations in its use. In hindsight, chief amongst them was the lack of definition of scientific independence, which made it difficult to verify its implementation by involved parties, despite their commitment. Secondly, the concept of the "ENCePP Seal," developed as an option to formalise both the commitment to the Code and the application of ENCePP methodological standards, 3, 4 was often misunderstood as suggesting that some provisions of the Code were optional and would only apply if the Seal was requested. Thirdly, the principle of conflict of interest referred almost exclusively to financial or commercial interests without considering the importance of the influence that institutional or personal interests may have on outcomes of research. 5 And finally, the Code had initially been created before the EU pharmacovigilance legislation came into force in 2012 and experience with the implementation of this meant that clarifications were needed as to how some provisions would apply to postauthorisation safety studies (PASS). 6 A major revision of the Code was therefore undertaken in 2017 and completed in 2018.
| The fourth revision
The key changes to address these deficiencies in the fourth revision are as follows. The spirit of the revision was to further move the balance from principles to practical solutions.
| New definition of scientific independence
After much deliberation, scientific independence is now defined as follows: that any financial, commercial, institutional, or personal interest in a particular outcome of the study (ie, in the results and their interpretation) at the level of the organisation initiating or funding the study and of the researcher(s) conducting the study, shall not influence any decision on the scientific aspects of the study in any particular direction, including the data collection and the analysis, interpretation, and dissemination of the study results.
KEY POINTS
• The Code is a unique source of practical guidance on scientific independence and transparency in the relationship between investigators and funders.
• The Code's fourth revision supports the scientific integrity of noninterventional postauthorisation research.
• Compliance with the Code protects researchers and study funders from threats to scientific independence related to commercial, financial, institutional, or personal interests.
• Researchers, from the funding organisation shall not participate in study activities that could influence the results or their interpretation in any particular direction.
| More clarity on different categories of interest
Four categories of relevant interests are described: commercial, financial, institutional, and personal. In particular, it is now specified that commercial interests refer to the interests of organisations marketing the drug under study. The provisions of the Code now invest the four categories in a more articulated way.
Indeed, in the previous version of the Code, the requirement was that after protocol finalisation, no person with a commercial, financial, institutional, or personal interest in a particular outcome of the study could take part in any study activity that could influence the results or interpretation in any particular direction. This provision was considered as having undesired consequences and was modified in the current revision. Currently, all members of the study team are first requested to declare all existing direct and potential indirect interests of a commercial, financial, institutional, or personal nature that might impact their impartiality in relation to the study, and their declarations must be made available in the EU PAS Register. Second, specific provisions concern commercial, financial, or institutional interests only:
persons with such interests may not take the role of the primary lead investigator and may not participate in activities after protocol finalisation that may impact the results or their interpretation, unless no other specific technical expertise needed for the conduct of the study can be obtained in the study team. In addition, they may not have a decision-making role in the meetings of the steering group (if applicable), where they may be invited as specialists.
| Supporting applicability in regulatory studies
For studies requested by a regulatory authority to which legal requirements apply, the Code specifies that the final protocol should be agreed between the primary lead investigator, the study funder and the competent authority, even if the final responsibility of the protocol remains with the primary lead investigator. This provision complements the Good Pharmacovigilance (see: https://www.ema.europa.
eu/en/human-regulatory/post-authorisation/pharmacovigilance/ good-pharmacovigilance-practices) Practices (GVP) Module VIII requirement that the study protocol should be developed by individuals with appropriate scientific background and experience. 6 
| Comparison with other guidelines
In order to assess how the fourth revision fulfils an unmet need in pharmacoepidemiological research, we mapped the main recommendations of the revised Code with those of the International Society for Pharmacoepidemiology (ISPE) Good Pharmacoepidemiology Practices (GPP) 8 and of the ADVANCE Code of Conduct. 9 Table 1 provides the main recommendations from each guideline for the main topics addressed by the Code.
Although there are similarities between the three guidelines, there are also important differences explained by their differing objectives:
the Code aims to establish the concepts of scientific independence and transparency in the relationship between investigators and study funders, the ISPE GPP aims to ensure the scientific quality and integrity of pharmacoepidemiological studies and the ADVANCE Code of Con- to strengthen the confidence in the integrity and value of the research.
To help ensure the quality and integrity of research; to facilitate transparency and ethical integrity.
To support effective collaborations and clear governance for the conduct of collaborative postauthorisation vaccine studies.
Scope
Noninterventional postauthorisation studies
All types of pharmacoepidemiological (PE) research.
Postmarketing vaccine benefit-risk monitoring activities.
Guiding principles Scientific independence and transparency
Sound PE research, framework for conducting and evaluating PE studies, appropriate utilisation of technical resources, transparency, ethical integrity
Best science, strengthening public health, transparency Participants Protocol developed by individuals with appropriate scientific background and experience, but after protocol finalisation, no person with commercial, financial, institutional, or personal interest in any outcome of the study should be part of any study activity that could influence results or interpretation.
Personnel should have education, training or experience necessary to perform the assigned functions.
All study team members to be qualified and to act in accordance with values of honesty, accuracy, and objectivity.
Rights and obligations Primary lead investigator (PLI) ultimately responsible for study protocol, study conduct, and analysis, interpretation, and publication of results; study funder to be kept informed of study progress (eg, progress with recruitment but not interim results).
Organisation(s) or individuals conducting and sponsoring the research to be fully responsible; roles and responsibilities to be described.
Responsibility for scientific integrity to be shared by collaborating institutions. Right for the study sponsor to inspect the contractor's facilities and perform audit.
No undue influence of any financial, commercial, institutional, or personal interest in a particular outcome of the study. Clear and transparent roles and responsibilities.
Declaration of interests Direct and indirect commercial, financial, institutional, or personal interests to be declared by core team members and made public.
Potential conflicts of interest, financial and nonfinancial, to be disclosed in manuscripts.
Documented autonomy of study team members for making decisions in their organisation. Regulatory updated declarations of interest to be disclosed.
Study protocol to include sections on funding, affiliations, and potential conflicts of interest.
Actual or potential conflicts of interest to be addressed at the planning phase and their management to be included in research contract.
Research contract PLI to be without financial, commercial or institutional interest that could influence study in any particular direction.
If shared responsibility, research contact to delineate roles and responsibilities of study sponsor and contractor.
Should not lead investigators to act against the Helsinki declaration or applicable legislation.
Clarity and transparency. ADVANCE CoC to be referred to.
(Continues) 
ADVANCE Code of Conduct
Full compliance with ENCePP CoC to be referred to in contract. List of aspects to be addressed.
List of elements to be included.
Study protocol
To be developed with appropriate scientific background and experience.
ENCePP Checklist for study protocols to be consulted.
Process for protocol agreement on design options between PLI and study funder to be agreed beforehand. Protocol to be published in EU PAS Register before start of study. Amendments to be documented.
To be drafted as one of first steps in research project and to be amended or updated throughout the course of study.
Detailed description of content of protocol, to be included in case no regulatory guidance exists. Significant deviations to be documented in writing.
Registration of protocol in public site is welcomed without the option to retract the protocol.
To be drafted as one of first steps in research project and developed with persons of relevant expertise. Process for decision making to be agreed beforehand.
Contribution of each party to study design, protocol writing, and study work programme to be described. Independent scientific review by external experts.
To be amended as needed and changes to be identifiable.
To be registered in publicly available database before data collection.
Study registration Study to be registered in EU PAS Register by PLI and entry to be regularly updated
Registration of PE research in public site (EU PAS Register, clintrial.gov) is welcomed.
Study to be registered in publicly available database before start of data collection or extraction.
Study conduct Once the protocol is finalised, no person with commercial, financial, or institutional interest in any outcome of the study to be part of any study activity that could influence the results or interpretation thereof in any particular direction, except if technical expertise needed.
Post hoc analyses to be done only to generate further hypotheses. Members of steering group must be without direct or indirect commercial, financial, or institutional interests.
Persons with interests may be appointed as invited specialists without involvement in decision making. Composition of steering group to be made publicly available.
PI to be responsible for overall content of the research.
Decisions to terminate the study to be based on good scientific and ethical reasons and documented in writing. Description of procedures for data collection, management, and verification to be followed.
All data management and statistical analysis programmes used in analyses to be documented and archived.
Analysis to be directed towards unbiased estimation of the epidemiological parameter of interest; use of confidence intervals and sensitivity analyses.
Sensitivity analyses to be planned. Additional analyses based on study results to be presented as such and used only to generate further hypotheses.
Plan to handle missing and noninterpretable data to be developed.
Study results
Review of results by independent experts and PLI to address recommended changes and justify why changes are not accepted.
PLI to respond to requests by third parties.
Description of format and content of study report to be included.
Interpretation of study results to be the responsibility of the study team.
Important safety concerns to be documented and evaluated.
(Continues) Deviations from study protocol to be clearly documented. STROBE statement to be followed. Draught report to undergo independent scientific review.
Dissemination and publication Dissemination strategy to be predefined Summary of results in the EU PAS Register within 3 months.
PLI has the right to prepare publication irrespective of data ownership; study funder entitled to view the final results and interpretations and provide comments. ICMJE guidelines to be followed.
Ethical obligation to disseminate findings of potential scientific or public health importance.
Procedures for communications of the intent, conduct, results, and interpretation of epidemiology results to be predetermined. Recommendations for format of results to be reported. ICMJE guidelines to be followed.
PI and study team to be allowed by contract to publish independently from study funder.
All study results to be made available and intermediate results to be presented or published based on procedure agreed in advance; significant results of public health importance to be published rapidly with statement of their preliminary nature; regulatory and public health authorities to be rapidly informed of study results. Source of funding, affiliation, and potential conflicts of interests to be presented.
Study report or summary of results to be included in publicly accessible database. ICMJE guideline to be followed.
Data ownership and sharing. Rights of ownership of data and results to be included in research contract.
Rules for access to raw data, processed data, and results to be specified in protocol and research contract. Verification of published results to be allowed Data transformation steps to be described on request.
Analytical data set to be shared based on justification of public health interest and compliance to the Code of Conduct or audit by authority.
Open and collaborative approach to be adopted.
Data to be shared only after study report finalised.
Data sharing to be based on a written request justifying public health interest. Decision to share data to be taken by study team Analysis of shared data to follow ADVANCE CoC.
Protection of human subjects, confidentiality Confidential information to be defined in advance and specified in research contract or separate document.
Approval by IRB or IEC to be obtained with exceptions in some countries. Confidentiality to be maintained; personal identifiers to be removed or protected.
Protocol to describe data protection and incentives for study subjects. Applicable legislation to be followed.
Abbreviations: CoC: Code of Conduct; GVP, EU Good Pharmacovigilance Practices; ICMJE, International Committee of Medical Journal Editors; IRB, institutional review board; IEC, independent ethics committee; PI, principal investigator (GPP); PLI, primary lead investigator (ENCePP CoC).
• Usefulness: for which types of studies the Code was considered to be beneficial
• Clarity: whether the Code was considered to be clear and the least represented one was "patients and consumer organisations" (6 or 7%). On average, respondents assessed their knowledge about noninterventional postauthorisation studies as "fairly good"
(33 or 37.9%) or "expert" (31 or 35.6%).
In the "usefulness" dimension, the majority of the respondents overall indicated that the Code would benefit all or most of all studies (66 or 76%)
Regarding "clarity," patients and healthcare professionals were asked (a) if they understood and (b) if they found important the principles of scientific independence and transparency, and the answers were largely positive to both questions (14 or 87.5% and 15 or 93.7%, respectively). Respondents from the other categories were asked to rate the Code in terms of easiness to understand and apply.
The former was judged positively by a large majority of respondents (92%), whilst in the latter, a negative judgement prevailed in all categories (70%) but more so amongst pharmaceutical companies (88%). In the dimension of "trust," a large majority of respondents in all categories (83%, 69% in pharmaceutical industry) responded that the Code would reinforce their trust in the study results. In the "participation" dimension, a large majority (71%) declared that studies applying the Code were likely to encourage their participation (in the role corresponding to their category), except for pharmaceutical industry, where half of the respondents (50%) replied with a neutral or negative answer. In the dimension of "redundancy,"
the overlap with other guidelines was difficult to judge by half of the sample of patients and health professionals and by 42% in the category of public health body or regulators. Amongst those providing an answer, the majority (38 or 43.7% of the whole sample) considered that the Code is a good complement to other guidelines.
A complete report of the survey is available in the EU PAS Register (EUPAS26545).
| ENCePP stakeholders' perspective
The following section provides the perspective of the different stake- A grey area is still the exact point at which the contract is signed in relation to prior feasibility studies and the exact nature of those feasibility studies since the period before the contract is not covered by the Code. Some protection in studies, which go ahead to contract, is given by including prior feasibility studies transparently as part of the protocol.
From an academic perspective, a greater awareness and more explicit value placed on the Code by medical journals would be helpful, both in justifying the expenditure of resources in following the Code and in negotiating compliance with the Code with funders. Academics and journals however are aware that compliance with the Code is currently self-policed, and the resulting impact on public confidence may not be as high as desired. Further development of a compliance monitoring mechanism could be envisaged.
Finally, from an academic point of view, the issue of scientific independence and transparency will never be fully resolved, whilst industry retains so much of the responsibility for conducting medication safety (and benefit) research. If regulatory agencies were to fund more of this to be done in the public sphere, with industry contributing to a public funding pot, which was distributed via an independent public mechanism, this could meet the requirement of scientific independence and achieve efficiencies that are impossible with the current product-centred pharmacovigilance system.
| Industry perspective
There is general agreement on the key principles of scientific independence and transparency; however, the practical implementation of these principles for industry-funded studies performed for regulatory purposes is challenging.
In the previous version of the Code, a key issue was the interpretation that the Code did not allow involvement in the study conduct after protocol approval, even when the study funder was legally responsible to comply with regulatory requirements. From an industry perspective, the sponsor's or marketing authorisation holder's legal accountability cannot be transferred to a third party. Related to this, another aspect was that the epidemiological expertise of researchers employed by industry that adds value to a study as does the expertise from academic researchers was not really considered. In this respect, the Code's focus on conflicts of interest of the study funder was considered as not balanced, and conflicts of interest that may arise from personal interests of researchers seemed to be perceived less of a threat to scientific integrity.
For all these reasons, a revision of the Code was welcomed by industry in order to get a more clear definition of scientific independence; ensure that industry can fulfil its legal obligations in following the Code; allow some flexibility in the study team structure, as defined in the research contract; and support better collaboration, as well as increase the trust, between all involved stakeholders.
With the updated current version of the Code, some of the previous critics should be now obsolete. The changes introduced may ease the use of the Code when industry is the funder, even if this will be difficult to quantify. This is why it could be interesting to develop a metrics that would help to assess how often the Code is implemented, for which types of studies (required by regulators or not), from which funder. This could be implemented in the EU PAS Register. This would most probably be easier to implement than assessing the real compliance with the content of the Code.
| Contract research organisation perspective
The Code was so far not explicit on whether contract research organisations belonging to ENCePP could participate in a study compliant with the Code beyond protocol finalisation. CROs are usually forprofit private organisations providing scientific expertise in the protocol design, recruitment, monitoring, data management and analysis, study report, and publication of results. The new definition for conflict of interest usefully clarified that the outcome of a specific study being in one direction or another is not intended to be a commercial interest of the CRO or academic institution involved in the research contract.
| Regulatory perspective
Since its beginning, the ENCePP network has served as support for the European regulatory environment in the field of epidemiology. 1, 15, 16 The ENCePP network has also helped to facilitate the intro- The provisions of the Code foreseeing that studies requested by regulators are not only agreed with the study funder but also with the competent authority(ies) strengthens the scientific independence of the primary lead investigator, which seems particular important for studies funded by stakeholders with interests in the products investigated. Whilst it might be considered as additional burden, the opportunity to engage with the primary lead investigator at the early stages of protocol discussions might also help to improve the process of protocol agreement, to foster timely involvement in discussions of methodological, operational, and feasibility aspects and to decrease possible information loss when regulatory advice is only conveyed indirectly via parties interacting between regulators and the responsible study investigator. Such issues led to multiple rounds of regulatory comments on PASS protocols, 21 prolonging the process of protocol approval.
Regulatory agencies also frequently assess results of noninterventional studies that were not conducted based on regulatory requests. For these studies also, assurance of transparency and independence are important factors guiding considerations of assessment of these data.
It has to be further noted that strengthened concepts of transparency and independence of study investigators might help to meet critique that has been expressed regarding the conduct of epidemiological studies, including PASS. 22, 23 The generation of epidemiological evidence is sometimes relevant to support the early approval of medicines. This highlights the need for reinforcement of those concepts, to enhance trust in postapproval epidemiological research. 17, 24 Trust building is further supported by increased transparency and 
| Limitations of the Code
The expression "commercial interest in an outcome of the study" is clarified in the Code to refer to the legitimate interest of those organisations marketing drugs. However, it may be perceived that research institutes that rely on funding from pharmaceutical companies to thrive (if public or private not-for-profit) or to pursue their legitimate profit (if for-profit), may be subject to indirect, possibly unwanted, influence from their funders. Even though compliance with the Code does protect researchers and funders from this risk within the realm of a single study, it cannot avoid a more subtle influence, because of a perception that funders may select the institution, which will conduct the next study based on the result of previous studies, instead of professional reputation. A related risk is that investigators and researchers may be tempted to interpret evidence of negative results as need for further research, with the objective of attracting new funding. In Europe, according to the current legislation, the funders for pharmacoepidemiology studies requested by regulators are mostly manufacturers themselves, which are therefore the most common funders for European research institutions in pharmacoepidemiology.
This makes the risk of indirect influence higher than in the United
States, where public funding is substantial. The ADVANCE project attempted to address the indirect influence of study funders, by producing guidance on the selection of research institutions. Three models of selection were proposed, in increasing order of perceived independence: led by the study funder, led by a selection committee, led by an external body. 25 
| The way forward
The Code is perceived as useful but, at the same time, has to date been seen as potentially difficult to apply in practise. As discussed above, this is partly due to the inherent complexity of the relationships between study funders and investigators. It is hoped that the current major revision will help in clarifying and disseminating the provisions of the Code to support understanding of its advantages and promote its adoption. Examples of translation of principles of the Code into concrete actions should be made available that could also support training activities. 13 To reinforce trust in the actual application of the Code's provisions funders and investigators may decide to enter in the EU PAS Register together with the final study report, a final selfassessment of compliance with the Code, signed by all involved parties. Alternatively, an independent scientific committee overseeing the study conduct could also take the responsibility to review compliance with the Code. A periodic, independent review of a random sample of EU PAS Register records would also be useful. And health-care professionals and patients may have more trust in studies that generate the evidence they rely upon for their decisions on pharmaceutical treatments.
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